🇺🇸 FDA
Patent

US 11702423

BRM targeting compounds and associated methods of use

granted A61PA61P35/00A61P35/02

Quick answer

US patent 11702423 (BRM targeting compounds and associated methods of use) held by Prelude Therapeutics, Incorporated expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Prelude Therapeutics, Incorporated
Grant date
Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61P, A61P35/00, A61P35/02